These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35323156)

  • 1. Getting to the heart of the matter: the need for tailored cardiovascular prevention strategies in patients with HIV.
    Filip I
    AIDS; 2022 Apr; 36(5):N1-N3. PubMed ID: 35323156
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention strategies for cardiovascular disease in HIV-infected patients.
    Stein JH; Hadigan CM; Brown TT; Chadwick E; Feinberg J; Friis-Møller N; Ganesan A; Glesby MJ; Hardy D; Kaplan RC; Kim P; Lo J; Martinez E; Sosman JM;
    Circulation; 2008 Jul; 118(2):e54-60. PubMed ID: 18566315
    [No Abstract]   [Full Text] [Related]  

  • 3. Preventing cardiovascular disease in midlife women with HIV: An examination of facilitators and barriers to heart health behaviors.
    Stanton AM; Goodman GR; Robbins GK; Looby SE; Williams M; Psaros C; Raggio G
    J Women Aging; 2023; 35(3):223-242. PubMed ID: 35201972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease and HIV infection.
    Triant VA
    Curr HIV/AIDS Rep; 2013 Sep; 10(3):199-206. PubMed ID: 23793823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial.
    Zanni MV; Fitch K; Rivard C; Sanchez L; Douglas PS; Grinspoon S; Smeaton L; Currier JS; Looby SE
    HIV Clin Trials; 2017 Mar; 18(2):83-91. PubMed ID: 28277924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin is indicated for primary prevention of cardiovascular events in HIV-infected patients.
    Tornero C; Ventura A; Mafe M
    J Acquir Immune Defic Syndr; 2010 Aug; 54(5):560. PubMed ID: 20647827
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cardiovascular risk in HIV infected patients].
    Raimundo P; Miranda A; Ribeiro J; Mansinho K
    Acta Med Port; 2010; 23(4):669-76. PubMed ID: 20687996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.
    Lambert CT; Sandesara PB; Hirsh B; Shaw LJ; Lewis W; Quyyumi AA; Schinazi RF; Post WS; Sperling L
    HIV Med; 2016 Jun; 17(6):411-24. PubMed ID: 26611380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary.
    Grinspoon SK; Grunfeld C; Kotler DP; Currier JS; Lundgren JD; Dubé MP; Lipshultz SE; Hsue PY; Squires K; Schambelan M; Wilson PW; Yarasheski KE; Hadigan CM; Stein JH; Eckel RH
    Circulation; 2008 Jul; 118(2):198-210. PubMed ID: 18566320
    [No Abstract]   [Full Text] [Related]  

  • 10. Guidelines for the prevention and management of cardiovascular complications in HIV-infected patients receiving HAART: The Pavia Consensus Statement.
    Barbaro G
    Adv Cardiol; 2003; 40():226-32. PubMed ID: 14533558
    [No Abstract]   [Full Text] [Related]  

  • 11. Exploring Statins to Decrease HIV-Related Heart Disease Risk.
    Mitka M
    JAMA; 2015 Aug; 314(7):657-9. PubMed ID: 26222872
    [No Abstract]   [Full Text] [Related]  

  • 12. Inflammation and Fibrosis in HIV: Getting to the Heart of the Matter.
    Hsue PY; Tawakol A
    Circ Cardiovasc Imaging; 2016 Mar; 9(3):e004427. PubMed ID: 26951604
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV and Cardiovascular Disease - An Ounce of Prevention.
    Freiberg MS
    N Engl J Med; 2023 Aug; 389(8):760-761. PubMed ID: 37486752
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary cardiovascular prevention in people with HIV: what's the score?
    Woolley I; Boccara F
    AIDS; 2023 Mar; 37(3):547-548. PubMed ID: 36695366
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular risk and response to lipid lowering therapy in patients with HIV infection according to different recommendations.
    Pawlos A; Broncel M; Wlazłowska E; Jabłonowska E; Gorzelak-Pabiś P
    PLoS One; 2020; 15(12):e0244675. PubMed ID: 33373417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular diseases in people with HIV.
    Highleyman L
    BETA; 2002; 15(3):10-22. PubMed ID: 12765129
    [No Abstract]   [Full Text] [Related]  

  • 17. Complications of HIV disease and antiretroviral therapy.
    Currier JS; Havlir DV
    Top HIV Med; 2009; 17(2):57-67. PubMed ID: 19401608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The next decade: cardiovascular risks, outcomes, prevention, and treatment in pediatric HIV infection.
    Miller TL
    J Pediatr (Rio J); 2010; 86(1):3-5. PubMed ID: 20151098
    [No Abstract]   [Full Text] [Related]  

  • 19. The influence of healthcare financing on cardiovascular disease prevention in people living with HIV.
    Webel AR; Schexnayder J; Rentrope CR; Bosworth HB; Hileman CO; Okeke NL; Vedanthan R; Longenecker CT
    BMC Public Health; 2020 Nov; 20(1):1768. PubMed ID: 33228623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
    Magen E; Elbirt D; Sthoeger Z
    Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.